articleTop 1% cited

Intravitreal Bevacizumab (Avastin) in the Treatment of Proliferative Diabetic Retinopathy

Ophthalmology · 2006 · Vol. 113(10) · pp. 1695–1705.e6

Robert L. Avery✉(California Retina Consultants)Joel Pearlman(California Retina Consultants)Dante J. Pieramici(California Retina Consultants)Melvin Rabena(California Retina Consultants)Alessandro Castellarin(California Retina Consultants)Ma'an Nasir(California Retina Consultants)Matthew Giust(California Retina Consultants)Robert Wendel(California Retina Consultants)Arun Patel(California Retina Consultants)

View via DOI Publisher page

Retinal Diseases and Treatments Retinal Imaging and Analysis Retinal and Optic ConditionsMedicineBevacizumabDiabetic retinopathyOphthalmologyRetinopathyProliferative vitreoretinopathyDiabetes mellitusChemotherapyInternal medicineRetinal

MeSH terms

BevacizumabAdultAgedAged, 80 and overAntibodies, MonoclonalCapillary PermeabilityDiabetic RetinopathyFemaleFluorescein AngiographyHumansInjectionsIrisMaleMiddle AgedNeovascularization, Pathologic

Citations

798

FWCI

62.77

field-weighted impact

References

Percentile

100%

vs. same field & year

Citations per year

Cited by

Pharmacokinetics of Intravitreal Bevacizumab (Avastin)